临床试验/NCT03981796

NCT03981796进行中（未招募）3 期

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Tesaro, Inc.1 个研究点分布在 1 个国家目标入组 785 人开始时间: 2019年7月18日最近更新: 2025年9月3日

适应症

干预措施

试验速览

阶段: 3 期
状态: 进行中（未招募）
发起方: Tesaro, Inc.
入组人数: 785
试验地点: 1
主要终点: Parts 1 and 2: Progression-Free Survival (PFS) - investigator assessment

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

The participant, Investigator, study staff, and the Sponsor study team and its representatives will be blinded to the assigned treatment.

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•Part 1 and Part 2:
•Female participant is at least 18 years of age.
•Participant has histologically or cytologically proven endometrial cancer with recurrent or advanced disease.
•Participant must have primary Stage III or Stage IV disease or first recurrent endometrial cancer with a low potential for cure by radiation therapy or surgery alone or in combination and meet at least one of the following criteria;
•Participant has primary Stage IIIA to IIIC1 disease with presence of evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 based on Investigator's assessment. Lesions that are equivocal or can be representative of post-operative change should be biopsied and confirmed for the presence of tumor;
•Participant has primary Stage IIIC1 disease with carcinosarcoma, clear cell, serous, or mixed histology (containing greater than or equal to [>=] 10 percent carcinosarcoma, clear cell, or serous histology) regardless of presence of evaluable or measurable disease on imaging;
•Participant has primary Stage IIIC2 or Stage IV disease regardless of the presence of evaluable or measurable disease;
•Participant has first recurrent disease and is naïve to systemic anticancer therapy;
•Participant has received prior neo-adjuvant/adjuvant systemic anticancer therapy and had a recurrence or progression of disease (PD) >=6 months after completing treatment (first recurrence only).
•Participant has an ECOG performance status of 0 or
•Participant has adequate organ function.
•Part 2 only:
•Participants must have normal blood pressure (BP) or adequately treated and controlled hypertension (systolic BP lesser than or equal to [<=] 140 millimeter of mercury [mmHg] and diastolic BP <=90 mmHg).
•Participants must be able to take medication orally, by mouth (PO).

排除标准

•Part 1 and Part 2:
•Participant has received neo-adjuvant/adjuvant systemic anticancer therapy for primary Stage III or IV disease and:
•has not had a recurrence or PD prior to first dose on the study OR
•has had a recurrence or PD within 6 months of completing systemic anticancer therapy treatment prior to first dose on the study.
•Participant has had >1 recurrence of endometrial cancer.
•Participant has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-PD-ligand 1 (anti-PD-L1), or anti-PD-ligand 2 (anti-PD-L2) agent.
•Participant has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy, or immunotherapy) within 21 days or <5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.
•Participant has a concomitant malignancy, or participant has a prior non-endometrial invasive malignancy who has been disease-free for <3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.
•Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.
•Participant has not recovered (that is [i.e.], to Grade <=1 or to Baseline) from cytotoxic therapy induced AEs or has received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 21 days prior to the first dose of study drug.
•Participant has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.
•Participant is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.
•Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy.
•Participant has received, or is scheduled to receive, a live vaccine within 30 days before first dose of study treatment, during study treatment, and for up to 180 days after receiving the last dose of study treatment.
•Part 2 only:
•Participant has received prior therapy with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor.
•Participant has clinically significant cardiovascular disease.
•Participant has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
•Participant is at increased bleeding risk due to concurrent conditions.
•Participant has participated in Part 1 of this study

研究组 & 干预措施

Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab

Active Comparator

干预措施: Dostarlimab (Biological)

Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab

Active Comparator

干预措施: Carboplatin (Drug)

Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab

Active Comparator

干预措施: Paclitaxel (Drug)

Arm 2: Participants receiving placebo + carboplatin-paclitaxel followed by placebo

Placebo Comparator

干预措施: Placebo matching dostarlimab (Drug)

Arm 2: Participants receiving placebo + carboplatin-paclitaxel followed by placebo

Placebo Comparator

干预措施: Carboplatin (Drug)

Arm 2: Participants receiving placebo + carboplatin-paclitaxel followed by placebo

Placebo Comparator

干预措施: Paclitaxel (Drug)

Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib

Active Comparator

干预措施: Dostarlimab (Biological)

Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib

Active Comparator

干预措施: Carboplatin (Drug)

Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib

Active Comparator

干预措施: Paclitaxel (Drug)

Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib

Active Comparator

干预措施: Niraparib (Drug)

Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo

Placebo Comparator

干预措施: Placebo matching dostarlimab (Drug)

Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo

Placebo Comparator

干预措施: Carboplatin (Drug)

Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo

Placebo Comparator

干预措施: Paclitaxel (Drug)

Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo

Placebo Comparator

干预措施: Placebo matching Niraparib (Drug)

结局指标

主要结局

Parts 1 and 2: Progression-Free Survival (PFS) - investigator assessment

时间窗: Up to 6 years

Part 1: Overall survival

时间窗: Up to 6 years

次要结局

Parts 1 and 2: Disease control rate (DCR) - BICR and Investigator assessment(Up to 6 years)
Part 2: Cmin and Cmax of niraparib (nanograms per milliliter)(Predose (Day 1) and 3 hours postdose (Day 1) of Cycles 7 and 8 and Predose (Day 1) of Cycles 10 and 14 (each cycle is 42 days))
Part 2: Cmin and Cmax at steady state of niraparib (nanograms per milliliter)(Predose (Day 1) and 3 hours postdose (Day 1) of Cycles 7 and 8 and Predose (Day 1) of Cycles 10 and 14 (each cycle is 42 days))
Part 2: Overall survival(Up to 6 years)
Parts 1 and 2: PROs in the EORTC Quality of Life Questionnaire (Endometrial Cancer Module [QLQ-EN24])(Up to 6 years)
Parts 1 and 2: Progression-free survival 2 (PFS2)(Up to 6 years)
Parts 1 and 2: Change from Baseline in vital sign: Respiratory rate(Baseline and up to 6 Years)
Parts 1 and 2: Number of participants with Eastern Cooperative Oncology Group (ECOG) Performance Status Scores(Up to 6 years)
Parts 1 and 2: Number of participants with clinically significant changes in clinical laboratory parameters, physical examination, electrocardiogram (ECG) and participants reporting the intake of concomitant medication(Up to 6 years)
Parts 1 and 2: Change from Baseline in vital sign: Heart Rate(Baseline and up to 6 Years)
Parts 1 and 2: Number of participants with adverse events (AEs), Serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)(Up to 6 years)
Parts 1 and 2: Change from Baseline in vital sign: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (Millimeters of mercury)(Baseline and up to 6 Years)
Parts 1 and 2: Progression free survival (PFS) blinded independent central review (BICR)(Up to 6 years)
Parts 1 and 2: Objective response rate (ORR) - BICR and Investigator assessment(Up to 6 years)
Parts 1 and 2: Duration of response (DOR) - BICR and Investigator assessment(Up to 6 years)
Parts 1 and 2: Patient-reported outcomes (PROs) in the European Quality of Life scale, 5-Dimensions, 5-Levels (EQ-5D-5L)(Up to 6 years)
Parts 1 and 2: PROs in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30 [Core])(Up to 6 years)
Parts 1 and 2: Change from Baseline in vital sign: Body temperature(Baseline and up to 6 Years)
Parts 1 and 2: Minimum observed concentration (Cmin) and maximum observed concentration (Cmax) of dostarlimab (micrograms per milliliter)(Predose (Day 1) and postdose (Day 1) of Cycles 1, 2, 6, 7, 10, 15, and 20 (Cycle 1, 2, 6 is 21 days and Cycle 7, 10, 15, 20 is 42 days))
Parts 1 and 2: Cmin and Cmax at steady state of dostarlimab (micrograms per milliliter)(Predose (Day 1) and postdose (Day 1) of Cycles 1, 2, 6, 7, 10, 15, and 20 (Cycle 1, 2, 6 is 21 days and Cycle 7, 10, 15, 20 is 42 days))
Parts 1 and 2: Number of participants with anti-drug antibodies (ADA) against dostarlimab(Predose (Day 1))

研究者

发起方

Tesaro, Inc.

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

2 期

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerCarcinoma

NCT06317311GlaxoSmithKline41

进行中（未招募）

3 期

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)Lung Cancer, Non-Small Cell

NCT06472076GlaxoSmithKline88

进行中（未招募）

2 期

Dostarlimab and Cobolimab in Advanced Cervical CancerAdvanced Cervical CarcinomaMetastatic Cervical CancerMetastatic Cervical CarcinomaRecurrent Cervical CarcinomaCervical Cancer

NCT06238635Meghan Shea66

招募中

2 期

Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaPenile Carcinoma

NCT05526989H. Lee Moffitt Cancer Center and Research Institute25

招募中

2 期

SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)Endometrial Cancer Stage IMmr DeficiencyEndometrioid Endometrial AdenocarcinomaImmune-related Adverse Event

NCT06278857Queensland Centre for Gynaecological Cancer10